Navigation Links
Genesis Biopharma Announces Termination of Previously Announced Proposed Public Offering
Date:5/7/2012

LOS ANGELES, May 7, 2012 /PRNewswire/ -- Genesis Biopharma, Inc. (OTCBB: GNBP), a biotechnology company developing targeted cancer immunotherapies, announced today that it is terminating its previously announced proposed public offering pursuant to a preliminary prospectus supplement and an effective shelf registration statement on file with the Securities and Exchange Commission due to market conditions. 

"The Company intends to pursue alternative financing under more favorable conditions", stated Anthony Cataldo, President & Chief Executive Officer of Genesis Biopharma, Inc. 

About Genesis Biopharma, Inc.

Genesis Biopharma, Inc. is engaged in the development and commercialization of autologous cell therapies for the treatment of various cancers.  The company's lead product candidate, Contego™, is a ready-to-infuse autologous cell therapy utilizing tumor infiltrating lymphocytes for the treatment of patients with Stage IV metastatic melanoma.  Contego™ is based on a currently available physician-sponsored investigational therapy at the National Cancer Institute, MD Anderson Cancer Center and the H. Lee Moffitt Cancer & Research Institute for the treatment of Stage IV metastatic melanoma. 

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks detailed from time to time in the company's filings with the Securities and Exchange Commission, and represent the company's views only as of the date they are made and should not be relied upon as representing the company's views as of any subsequent date.  The company does not assume any obligation to update any forward-looking statements.


'/>"/>
SOURCE Genesis Biopharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. ThermoGenesis Corp. To Announce Third Quarter Fiscal 2012 Results On May 10, 2012
2. ThermoGenesis Announces AABB Accreditation for Cord Blood Products Customer in China
3. ThermoGenesis Announces Webcast of Presentation at Roth Capital Conference
4. ThermoGenesis Reports Second Quarter Fiscal 2012 Results
5. Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others
6. ThermoGenesis Provides Update on Res-Q® Clinical Evaluations at Leading Stem Cell Therapy Conference
7. Canadas First National Public Cord Blood Bank Adopts ThermoGenesis BioArchive Cryopreservation System
8. Thermogenesis Signs Worldwide Res-Q System Distribution Agreement With Arthrex for Sports Medicine Applications
9. ThermoGenesis Announces Webcast of Presentation at OneMedForum Conference
10. Genesis Biopharmas Scientific and Medical Advisory Board Welcomes Dr. Steven A. Rosenberg, Chief of the Surgery Branch at the NCI
11. Triple Analysis: Prostate Cancer, Angiogenesis and Peptides
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... March 26, 2015  Oxis Biotech, Inc. ... International, Inc. [OTC: OXIS] and [Euronext Paris: ... exclusive option agreement with the University of ... by Dr. Xiang-Qun Xie , Associate ... Sciences, School of Pharmacy.  These patents/intellectual properties ...
(Date:3/26/2015)... -- IGI Laboratories, Inc. (NYSE MKT: IG), a ... company, today announced it has submitted its first abbreviated ... Drug Administration (FDA) of 2015, which brings the Company,s ... FDA to twenty-three. Jason Grenfell-Gardner , ... 2, 2015, we committed to file at least twenty ...
(Date:3/26/2015)... 26, 2015  CNBC profiled MJ Freeway , a ... a series "How I Did It," which features companies with ... Road" released yesterday, illustrates how two tech entrepreneurs from ... providers to the marijuana industry. ... Co-Founders Amy Poinsett and Jessica Billingsley used their ...
Breaking Medicine Technology:Oxis Biotech Executes Option Agreement to Certain Patents/Intellectual Properties Owned by the University of Pittsburgh 2Oxis Biotech Executes Option Agreement to Certain Patents/Intellectual Properties Owned by the University of Pittsburgh 3IGI Laboratories, Inc. Announces First ANDA Submission Of 2015 2MJ Freeway, Industry-Leading Software Solution for Cannabis Businesses, Featured in CNBC Special "How I Did It" 2
... ... Fibrillation Patients, CARLSBAD, Calif., Jan. 16 Ablation ... U.S.,Investigational Device Exemption (IDE) clinical trial for interventional,treatment of chronic atrial ... proceed with the pivotal phase of the,study is based on the ...
... Jan. 16 Cerimon,Pharmaceuticals, Inc., announced today it ... studies of its once-,daily topical diclofenac sodium patch ... studies, designated the "SUPPORT" (Stop Underlying Pain with ... assess the,efficacy and safety of Cerimon,s patch compared ...
Cached Medicine Technology:FDA Grants Approval to Extend U.S. Enrollment and Clinical Trial 2FDA Grants Approval to Extend U.S. Enrollment and Clinical Trial 3Cerimon Pharmaceuticals Initiates Phase II/III Clinical Studies to Evaluate its Diclofenac Patch for Mild to Moderate Pain 2Cerimon Pharmaceuticals Initiates Phase II/III Clinical Studies to Evaluate its Diclofenac Patch for Mild to Moderate Pain 3
(Date:3/26/2015)... 26, 2015 In the key developed markets, ... 2013 and is set to decrease through 2020 at a ... growth is expected up to 2017 at a 2.6% CAGR ... be owing to the surging penetration of fixed-dose combination drugs ... Plus, Valturna, Benicar HCT, and Tekamlo), a hike in the ...
(Date:3/26/2015)... In preparation for the 2016 United States ... Samir Becic, has issued “report cards” for potential ... fitness, as well as their promotion of health and ... Ted Cruz, who has officially announced his candidacy for ... who have shown interest in running for office. This ...
(Date:3/26/2015)... With the rapidly growing healthcare market and consumers ... its not just doctors who are now purchasing medical ... a piece of the action. HealthSource Chiropractic ®, the ... franchises purchased by people with no health backgrounds to ... Chiropractic is an exploding $12.7 billion dollar market with ...
(Date:3/26/2015)... 26, 2015 The beauty industry united ... a man who revolutionized the business of beauty education. ... Passage; founder of Pivot Point International, Inc. Passage’s wife ... of Leo. Held at the Art Institute of Chicago, ... of industry and media leaders and served as the ...
(Date:3/26/2015)... LinkToBanking, a Preferred Partner Network for the cannabis ... of the Board and Robert Casares as Vice-Chairman ... combined knowledge and experience in regulatory compliance and ... Casares will provide exceptional guidance on how to ... About Tom Fleming, Mr. Fleming, CAMS, has over ...
Breaking Medicine News(10 mins):Health News:Top 8 Developed Anti-Hypertensive Therapeutics Markets Discussed in New GBI Research Report Published at MarketPublishers.com 2Health News:Top 8 Developed Anti-Hypertensive Therapeutics Markets Discussed in New GBI Research Report Published at MarketPublishers.com 3Health News:How the Candidates for the 2016 Presidential Election Rank in Health and Fitness 2Health News:How the Candidates for the 2016 Presidential Election Rank in Health and Fitness 3Health News:HealthSource Chiropractic Franchise Expands National Footprint as Investors Buy In 2Health News:HealthSource Chiropractic Franchise Expands National Footprint as Investors Buy In 3Health News:#BeautyChangesLives Legacy Award Pays Tribute to Industry Icon Leo Passage 2Health News:#BeautyChangesLives Legacy Award Pays Tribute to Industry Icon Leo Passage 3Health News:Tom Fleming named Chairman of the Board and Robert Casares as Vice-Chairman of the Board of LinkToBanking 2Health News:Tom Fleming named Chairman of the Board and Robert Casares as Vice-Chairman of the Board of LinkToBanking 3
... team of researchers, including a number from the University of ... regions of the genome that contribute to the debilitating lung ... Their findings provide insight into the causes of the wide ... also points the way to new diagnostic markers and therapeutic ...
... , MONDAY, May 23 (HealthDay News) -- Cancer patients who ... greater sense of satisfaction about their treatment, a new study ... and accurate medical information built trust between patient and doctor. ... , the study analyzed 295 patients recently diagnosed with lymphoma, ...
... Monday, May 23, 2011 New findings out of Wake Forest ... in predicting early death in individuals with diabetes. ... Care . "People with diabetes are already at high risk ... W. Bowden, Ph.D., the director of the Center for Diabetes Research ...
... 22, 2011- Gothenburg, Sweden : The aldosterone antagonist ... new onset atrial fibrillation and flutter (AFF) in ... sub-analysis of the EMPHASIS-HF trial, presented at the ... Failure Association of the European Society of Cardiology ...
... Although chemotherapy is used to kill cancer cells, it ... such as bone marrow and blood cells, often limiting the ... Fred Hutchinson Cancer Research Center reported at today,s annual meeting ... Seattle that one possible approach to reduce this toxic effect ...
... , FRIDAY, May 20 (HealthDay News) -- The ... skin -- is significantly higher among overweight and obese kids, ... online in the Journal of Pediatrics , also found ... higher cholesterol levels, putting them at greater risk for heart ...
Cached Medicine News:Health News:Consortium identifies genome regions that could influence severity of cystic fibrosis 2Health News:Consortium identifies genome regions that could influence severity of cystic fibrosis 3Health News:Cancer Patients Benefit From Full Access to Medical Records 2Health News:Common test could help predict early death in diabetes, study shows 2Health News:Common test could help predict early death in diabetes, study shows 3Health News:EMPHASIS HF: Study shows epleronone to reduce atrial fibrillation 2Health News:EMPHASIS HF: Study shows epleronone to reduce atrial fibrillation 3Health News:Gene-modified stem cells help protect bone marrow from toxic side effects of chemotherapy 2Health News:Study Sees Link Between Psoriasis, Obesity in Kids 2
... IDT six-slice imaging system provides advanced ... innovations to maximize performance and minimize ... to delivering optimal clinical results, Mx8000 ... multislice CT today and the foundation ...
... The Mx8000 IDT 10 offers premium-level performance with ... on any other systems in the 8- and ... 0.4 second rotation time, and submillimeter isotropic imaging ... interface and a simple upgrade to a 16-slice ...
... for everyday, 1/2-second high-speed scanning, Aquilion ... image resolution with longer, faster helical ... imaging., An improved X-ray tube and ... this supercharged CT scanner, giving it ...
... to facilitate disc removal, endplate preparation and ... fusion. The TLIF instruments are very low ... for which they were primarily designed, however ... in PLIF and ALIF. Disc rongeurs: used ...
Medicine Products: